Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renewal of Intestinal Stem Cells01:23

Renewal of Intestinal Stem Cells

2.6K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.6K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation of a Ym1 deficient mouse utilising CRISPR-Cas9 in CB6 embryos.

Transgenic research·2025
Same author

Leveraging metabolic modeling to identify functional metabolic alterations associated with COVID-19 disease severity.

Metabolomics : Official journal of the Metabolomic Society·2022
Same author

Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.

mSphere·2021
Same author

Solitary and periodic waves in collisionless plasmas: The Adlam-Allen model revisited.

Physical review. E·2020
Same author

Enhanced monocyte recruitment and delayed alternative macrophage polarization accompanies impaired repair following myocardial infarction in C57BL/6 compared to BALB/c mice.

Clinical and experimental immunology·2019
Same author

Management of Barrett's esophagus with low-grade dysplasia.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2018
Same journal

Anti-biofilm activity of coated zinc oxide nanoparticles in a water-in-oil formulation against Cutibacterium acnes.

Anaerobe·2026
Same journal

The Impact of Fecal Microbiota Transplantation on Host Immunity and Epithelial Restoration Following Clostridioides difficile Infection.

Anaerobe·2026
Same journal

Evaluation of molecular thresholds based quantification of Gardnerella vaginalis and Fannyhessea vaginae for improved diagnosis of Bacterial Vaginosis.

Anaerobe·2026
Same journal

<sup>1</sup>H NMR metabolomic profiling of Methanobacterium and Methanosarcina reveals unusual intracellular trimethylamine and acetamide production.

Anaerobe·2026
Same journal

Reproducibility Assessment of the Crystal Violet Biofilm Assay in Clostridioides difficile.

Anaerobe·2026
Same journal

Clostridioides difficile in chicken fresh meat at retail in France.

Anaerobe·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.5K

IL-13 protects from Clostridioides difficile colitis.

A N Donlan1, J L Leslie2, M E Simpson3

  • 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, 98109, USA; Division of Infectious Diseases & International Health, University of Virginia, Charlottesville, VA, 22908, USA.

Anaerobe
|May 3, 2024
PubMed
Summary
This summary is machine-generated.

Interleukin-13 (IL-13) administration protected against Clostridioides difficile infection (CDI) in mice, while blocking IL-13 worsened disease. This highlights IL-13

Keywords:
C. difficileIL-13ImmunityType 2 immunity

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Related Experiment Videos

Last Updated: Jun 27, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.5K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Area of Science:

  • Immunology
  • Microbiology
  • Gastroenterology

Background:

  • Clostridioides difficile infection (CDI) is a major hospital-acquired infection.
  • Antibiotic use disrupts gut microbiota, reducing protective cytokines like IL-33 and IL-25.
  • IL-33 signaling via ILC2s produces IL-13, but IL-13's role in CDI was unknown.

Purpose of the Study:

  • To investigate the role of IL-13 in a mouse model of CDI.
  • To determine if IL-13 influences disease severity and immune cell responses during CDI.

Main Methods:

  • Utilized a validated mouse model of CDI.
  • Administered recombinant IL-13 or blocking antibodies against IL-13.
  • Analyzed disease severity using weight loss and clinical scores.
  • Characterized myeloid cell populations using fluorescent activated cell sorting (FACS).

Main Results:

  • IL-13 administration conferred protection against CDI.
  • Blocking IL-13 exacerbated CDI severity.
  • IL-13 neutralization altered monocyte/macrophage populations and increased myeloid cell accumulation.
  • Neutralizing the IL-13 decoy receptor (IL-13Rα2) protected against CDI.

Conclusions:

  • IL-13 plays a protective role in CDI, mitigating disease severity.
  • Dysregulation of the monocyte/macrophage compartment is associated with poor responses to CDI.
  • Findings enhance understanding of type 2 immunity in CDI and suggest therapeutic potential.